hydroxyprogesterone caproate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 4189 630-56-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxyprogesterone caproate
  • 17-alpha-hydroxy-progesterone caproate
  • delalutin
  • 17alpha-hydroxyprogesterone
  • makena
  • 17alpha-Hydroxyprogesterone hexanoate
  • hydroxyprogesterone hexanoate
  • progesterone caproate
  • gestageno
  • hydroxyprogesterone caproate
Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.
  • Molecular weight: 428.61
  • Formula: C27H40O4
  • CLOGP: 5.99
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 0
  • TPSA: 60.44
  • ALOGS: -5.69
  • ROTB: 7
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1 32
kinase-selectivity-class EIF2AK3,GRK2 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 3, 1975 FDA ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Preterm premature rupture of membranes 1662.07 70.49 254 7305 1387 90619501
Premature baby 1344.39 70.49 329 7230 24748 90596140
Injection site pruritus 1235.75 70.49 361 7198 53473 90567415
Injection site pain 1176.18 70.49 465 7094 173234 90447654
Premature labour 612.46 70.49 155 7404 13221 90607667
Injection site mass 584.79 70.49 166 7393 21924 90598964
Injection site swelling 568.06 70.49 206 7353 59633 90561255
Uterine contractions during pregnancy 543.71 70.49 85 7474 544 90620344
Product dose omission issue 542.61 70.49 323 7236 291364 90329524
Inappropriate schedule of product administration 512.08 70.49 249 7310 149684 90471204
Product administration error 457.21 70.49 143 7416 26280 90594608
Injection site erythema 420.38 70.49 191 7368 98311 90522577
Injection site nodule 377.28 70.49 85 7474 4388 90616500
Cervical incompetence 326.14 70.49 55 7504 593 90620295
Breech presentation 314.51 70.49 59 7500 1208 90619680
Induced labour 250.56 70.49 47 7512 961 90619927
Shortened cervix 240.21 70.49 37 7522 211 90620677
Injection site rash 239.26 70.49 86 7473 24087 90596801
Amniotic cavity infection 235.29 70.49 47 7512 1349 90619539
Premature separation of placenta 183.53 70.49 42 7517 2320 90618568
Injection site warmth 175.85 70.49 63 7496 17452 90603436
Pre-eclampsia 171.02 70.49 55 7504 10993 90609895
Injection site urticaria 159.29 70.49 59 7500 17952 90602936
Abortion spontaneous 149.22 70.49 78 7481 53978 90566910
Injection site bruising 140.18 70.49 74 7485 52233 90568655
Stillbirth 139.97 70.49 43 7516 7400 90613488
Product prescribing error 136.26 70.49 61 7498 30084 90590804
Cervical dilatation 131.54 70.49 16 7543 3 90620885
Premature delivery 127.56 70.49 63 7496 38699 90582189
Therapy cessation 116.39 70.49 58 7501 36303 90584585
Product administered at inappropriate site 113.26 70.49 32 7527 4119 90616769
Gestational diabetes 109.73 70.49 39 7520 10543 90610345
Limb discomfort 105.22 70.49 55 7504 38005 90582883
Drug ineffective 102.35 70.49 3 7556 1384295 89236593
Nonreassuring foetal heart rate pattern 102.16 70.49 15 7544 58 90620830
Maternal drugs affecting foetus 102.11 70.49 31 7528 5124 90615764
Injection site reaction 88.22 70.49 68 7491 92012 90528876
Pruritus 78.39 70.49 152 7407 541373 90079515
Gestational hypertension 76.32 70.49 22 7537 3040 90617848
Vaginal haemorrhage 74.66 70.49 41 7518 31230 90589658
Cervix cerclage procedure 71.66 70.49 11 7548 61 90620827
Placenta praevia 71.50 70.49 17 7542 1108 90619780

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature baby 2465.00 1178.66 366 131 22787 42598051

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Preterm premature rupture of membranes 1763.67 76.69 251 5862 1264 110581922
Injection site pain 1104.79 76.69 400 5713 177522 110405664
Injection site pruritus 1099.46 76.69 298 5815 50960 110532226
Premature labour 705.83 76.69 150 5963 9022 110574164
Product dose omission issue 552.00 76.69 293 5820 321489 110261697
Uterine contractions during pregnancy 539.65 76.69 78 6035 439 110582747
Inappropriate schedule of product administration 509.93 76.69 240 5873 203397 110379789
Injection site swelling 507.86 76.69 172 5941 61618 110521568
Injection site mass 493.11 76.69 136 5977 24477 110558709
Injection site erythema 398.71 76.69 161 5952 94015 110489171
Product administration error 375.23 76.69 121 5992 37096 110546090
Breech presentation 370.10 76.69 59 6054 686 110582500
Injection site nodule 362.89 76.69 77 6036 4569 110578617
Cervical incompetence 335.65 76.69 52 6061 495 110582691
Amniotic cavity infection 268.02 76.69 46 6067 861 110582325
Induced labour 260.22 76.69 45 6068 882 110582304
Shortened cervix 246.87 76.69 35 6078 167 110583019
Injection site rash 219.04 76.69 72 6041 23347 110559839
Premature separation of placenta 217.61 76.69 42 6071 1538 110581648
Pre-eclampsia 201.96 76.69 54 6059 8596 110574590
Injection site warmth 168.73 76.69 55 6058 17350 110565836
Injection site urticaria 153.21 76.69 51 6062 17164 110566022
Injection site bruising 144.94 76.69 66 6047 51197 110531989
Abortion spontaneous 132.37 76.69 55 6058 34227 110548959
Gestational diabetes 130.25 76.69 37 6076 7352 110575834
Cervical dilatation 129.33 76.69 15 6098 3 110583183
Premature delivery 127.98 76.69 52 6061 30580 110552606
Product prescribing error 123.14 76.69 59 6054 51272 110531914
Limb discomfort 113.57 76.69 52 6061 40802 110542384
Therapy cessation 96.88 76.69 48 6065 44809 110538377
Vaginal haemorrhage 96.01 76.69 40 6073 25034 110558152
Gestational hypertension 92.18 76.69 22 6091 2212 110580974
Maternal drugs affecting foetus 88.33 76.69 20 6093 1597 110581589
Oligohydramnios 79.50 76.69 22 6091 3972 110579214

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03DA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS
Pregnen (4) derivatives
ATC G03FA02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, fixed combinations
FDA CS M0447349 Progesterone Congeners
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D006728 Hormones
MeSH PA D011372 Progestins
FDA EPC N0000175602 Progestin
CHEBI has role CHEBI:25212 metabolite
CHEBI has role CHEBI:59826 progestin
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

G03DA Pregnen (4) derivatives 3 drugs
gestonoronemedroxyprogesteroneprogesterone
G03FA Progestogens and estrogens, fixed combinations 15 drugs
dienogestdrospirenonedydrogesteroneethisteroneetynodiollevonorgestrellynestrenolmedroxyprogesteronemegestrol acetatemethylestrenolonenorethisteronenorethynodrel show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Prevention of Premature Labor indication
Endometrial carcinoma off-label use 254878006 DOID:2871
Impaired glucose tolerance contraindication 9414007
Jaundice contraindication 18165001
Depressive disorder contraindication 35489007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Neoplasm of liver contraindication 126851005 DOID:3571
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Thromboembolic disorder contraindication 371039008
Carcinoma of female breast contraindication 447782002
Predisposition to Thrombosis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST IC50 7.66 SCIENTIFIC LITERATURE DRUG LABEL
Sodium-dependent dopamine transporter Transporter Ki 5.26 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.57 DRUG MATRIX
Corticosteroid-binding globulin Secreted Ki 7.74 CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 7.64 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 5.50 DRUG MATRIX
Sex hormone-binding globulin Secreted Kd 7 CHEMBL
Androgen receptor Transcription factor Ki 6.31 DRUG MATRIX
Progesterone receptor Transcription factor Ki 8.81 DRUG MATRIX

External reference:

IDSource
4017613 VUID
N0000179012 NUI
D00949 KEGG_DRUG
4017613 VANDF
4019781 VANDF
CHEBI:5812 CHEBI
CHEMBL1200848 ChEMBL_ID
DB06789 DRUGBANK_ID
DB14570 DRUGBANK_ID
1087965 RXNORM
179630 MMSL
3385 MMSL
4853 MMSL
7924 MMSL
d00554 MMSL
001291 NDDF
001293 NDDF
126110005 SNOMEDCT_US
126111009 SNOMEDCT_US
56014002 SNOMEDCT_US
C0044971 UMLSCUI
D000077713 MESH_DESCRIPTOR_UI
D019326 MESH_DESCRIPTOR_UI
C0045010 UMLSCUI
633 INN_ID
169870 PUBCHEM_CID
68-96-2 SECONDARY_CAS_RN
6238 PUBCHEM_CID
276F2O42F5 UNII
716 INN_ID
21807M87J2 UNII
CHEBI:17252 CHEBI
21807M87J2 INXIGHT DRUGS
276F2O42F5 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
HYDROXYPROGESTERONE CAPROATE Human Prescription Drug Label 1 47335-037 INJECTION 250 mg INTRAMUSCULAR ANDA 26 sections
Hydroxyprogesterone Caproate Human Prescription Drug Label 1 55150-311 INJECTION 1250 mg INTRAMUSCULAR ANDA 12 sections
Hydroxyprogesterone Caproate HUMAN PRESCRIPTION DRUG LABEL 1 69238-1797 INJECTION 250 mg INTRAMUSCULAR ANDA 24 sections